{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Exton",
      "state": "PA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "95190",
      "recalling_firm": "ProRx LLC",
      "address_1": "619 Jeffers Cir",
      "address_2": "",
      "postal_code": "19341-2540",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the USA",
      "recall_number": "D-0651-2024",
      "product_description": "Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01",
      "product_quantity": "37 vials",
      "reason_for_recall": "Lack of Assurance of Sterility",
      "recall_initiation_date": "20240822",
      "center_classification_date": "20240905",
      "report_date": "20240911",
      "code_info": "Lot #  ProRx040924-1, BUD 10/08/2024",
      "more_code_info": ""
    }
  ]
}